What top creators are saying about UnitedHealth Group Incorporated(UNH)— Page 3

Michael Burry, a prominent investor, has reportedly added $115 million of UnitedHealth Group (UNH) to his portfolio, signaling a bullish outlook.

Warren Buffett and David Tepper have recently increased their stakes, signaling strong institutional confidence.

Warren Buffett's Berkshire Hathaway purchased 5 million shares, which is considered a bullish indicator and a signal of confidence in the company.

Considered a potential bullish 'comeback trade' and a buying opportunity for a high-quality company while market sentiment is overly negative.

Noted as the #1 stock being bought by 'super investors' in the most recent quarter. Viewed as a potential defensive/value stock to own during a tech correction.

A Congressman with a role on the subcommittee investigating Medicaid purchased the stock, suggesting a potentially bullish outlook based on his informed position. This is seen as a speculative bet on a recovery.

Mentioned as one of the top buys by 'super investors' in Q2 2024 based on early 13F filings, suggesting positive institutional interest.

Considered 'cheap for a reason' due to a DOJ investigation and the risk of 'multiple compression.' The host sees it as a less attractive opportunity than tech stocks, despite a potential path to $400 over a five-year horizon.

Very bearish call, stating there is 'something flawed with their business model' and that the company has been 'playing games with their earnings.' The stock's 'stunning drop' is seen as confirmation of deep-seated problems.

Repeatedly mentioned as a potential 'value trap' that is cheap for a reason. The stock is facing narrative headwinds and a DOJ case, making it less attractive than other opportunities.

The stock 'has not found a bottom' and presents a 'pretty bad picture' due to climbing healthcare costs, a federal investigation, and a significant guidance cut. Speaker warns it's 'too early' for a turnaround investment.

While considered 'stupidly cheap' on a valuation basis, a guest advised against buying, calling it 'dead money' due to leadership changes, a DOJ investigation, and strong downward momentum.

Presented as a high-conviction, contrarian bull case. The thesis is that UNH has 'sandbagged' guidance, setting up years of future earnings beats driven by margin recovery and massive share buybacks.

Viewed with bearish sentiment, as the speaker explicitly stated, 'I don't like UNH.'

Neutral-to-bearish view, questioning the valuation for a non-growth business and seeing long-term headwinds from AI potentially lowering healthcare costs.

Stock dropped 7% after giving very weak 2025 profit guidance. Analysts believe the new CEO is setting a low bar, framing the stock as a '2026 turnaround story' requiring a long-term investment horizon.

The recent stock drop is viewed as a contrarian buying opportunity. The host believes the company is resilient and will rebound, suggesting a long-term call option trade to capitalize on a potential return to its previous high of $600.

Currently facing short-term pressure from higher medical costs, but viewed as a long-term, undervalued value play that is expected to recover over the next 3-4 years as it reprices insurance plans.

Presented as a deep value play requiring patience after missing on EPS and providing weak forward guidance of $16/share in earnings for 2025, well below expectations.

The speaker does not like the stock and is wary of the risk that the company may have to be 'permanently restructured,' advising caution.

Stock dropped due to a DOJ investigation, but its strong free cash flow may present a contrarian 'buy the dip' opportunity for investors with high-risk tolerance.

Considered a compelling 'deep value play' that is potentially 50-60% undervalued. The returning CEO's $60M compensation is tied to getting the stock price above $450.

After being 'obliterated', the stock is viewed as a 'potential deep value opportunity' and 'really freaking interesting' at its current levels around $282, now yielding over 3%.

Viewed as a fundamentally strong, undervalued 'buy and hold' candidate for patient investors after being beaten down, but a quick recovery is not expected.

Viewed as an industry leader and a safer investment in the sector. A guest is adding to their position below $300, seeing weakness as a buying opportunity.

The recent dip is framed as a clear buying opportunity for a 'ridiculously undervalued' company. A conservative valuation model suggests a stock price of $450 by 2030. The primary risk is a DOJ investigation.

Called 'objectively undervalued'. A conservative analysis yields a $450 price target. Broke out of a consolidation box, but needs to hold above $324.64 to continue. Faces headline risk from a DOJ investigation.

Highlighted as an undervalued value stock that performed well during a market rotation. It was specifically mentioned as a 'safety play' in case of a recession or growth scare.

Viewed as a deep value play, down 40% YTD, with a cheap valuation (11x forward earnings) and significant insider buying. An options trade was placed betting the stock will be above $460 in 2.5 years.

Viewed as a 'deep value play' trading at a low valuation with 50% upside potential. The speaker initiated a long-term bullish call debit spread trade based on insider buying and its defensive nature.

Viewed as significantly undervalued, trading at just 11 times free cash flow. A long-term options strategy was initiated, targeting a price of $460 by December 2027. The company is described as a 'blue chip business' with a durable moat and has seen recent insider buying.